Clinical-stage biopharmaceutical company developing multifunctional therapeutics for the treatment of cancer.
Zymeworks Inc. is an innovative clinical-stage biopharmaceutical company specializing in the discovery, development, and commercialization of biotherapeutics aimed at combating cancer. Central to its robust pipeline are lead product candidates such as zanidatamab, a cutting-edge bispecific antibody currently undergoing Phase 1 and Phase 2 clinical trials. Zanidatamab targets multiple cancers including biliary tract, gastroesophageal adenocarcinomas, breast, and colorectal cancer, highlighting Zymeworks' commitment to addressing diverse oncological challenges.
In addition to zanidatamab, Zymeworks is advancing ZW49, a biparatopic anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate in Phase 1 clinical trials. This innovative therapy is designed for the treatment of advanced or metastatic tumors expressing HER2, underscoring the company's dedication to developing targeted and effective treatments for cancer patients.
Beyond its clinical programs, Zymeworks maintains a robust pipeline of preclinical product candidates and discovery-stage programs focusing on immuno-oncology and other therapeutic areas. The company's strategic collaborations with leading pharmaceutical entities such as Merck Sharp & Dohme, Eli Lilly, Bristol-Myers Squibb, GlaxoSmithKline, Daiichi Sankyo, Janssen Biotech, BeiGene, and Exelixis further enhance its research and development capabilities.
Founded in 2003 and headquartered in Vancouver, Canada, Zymeworks Inc. continues to expand its global footprint in biopharmaceutical innovation. With a strong emphasis on scientific excellence and strategic partnerships, the company remains at the forefront of advancing novel therapies that have the potential to transform the treatment landscape for cancer and beyond.